1. Navigate to /generics-bulletin
  2. Navigate to /generics-bulletin/archive

Imraldi sets pace on German price cuts

 
• By Aidan Fry
  
Generate a summary of this article
Listen to this article
Beta

Biogen’s Imraldi (adalimumab) biosimilar has entered the German market with a list price just over 40% lower than the cost of the reference brand, AbbVie’s Humira, according to the association of statutory health insurance doctors for the North Rhine region, the KVNO. And while Amgen’s Amgevita and Sandoz/Hexal’s Hyrimoz currently offer more modest list-price discounts to Humira, the KVNO says both suppliers of adalimumab biosimilars have announced price cuts that will come into effect from 15 November.

Biogen’s Imraldi (adalimumab) biosimilar has entered the German market with a list price just over 40% lower than the cost of the reference brand, AbbVie’s Humira, according to the association of statutory health insurance doctors for the North Rhine region, the KVNO. And while Amgen’s Amgevita and Sandoz/Hexal’s Hyrimoz currently offer more modest list-price discounts to Humira, the KVNO says both suppliers of adalimumab biosimilars have announced price cuts that will come into effect from 15 November.

Citing data from Germany’s Lauer-Taxe price list, as well as company information, the KVNO says a pack of two Imraldi...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Archive

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Testing-Rising

 
• By Saba Afreen

Testing-Rising xxxx

bhvyuguig

lnkbkb

test 1

test 1

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C7

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.